Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCTH NASDAQ:LUNG NASDAQ:OM NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$11.25-0.6%$14.59$7.17▼$18.23$391.79M0.87450,417 shs722,832 shsLUNGPulmonx$3.15+1.9%$2.99$2.50▼$9.37$126.81M0.45313,961 shs356,914 shsOMOutset Medical$17.42-1.0%$19.29$5.85▼$62.10$308.72M2.15156,677 shs319,110 shsTMCITreace Medical Concepts$5.65-2.4%$6.01$4.54▼$10.79$355.33M0.69486,216 shs183,571 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems0.00%-0.79%-20.55%-3.27%+43.86%LUNGPulmonx0.00%+8.62%+14.55%-30.31%-61.01%OMOutset Medical0.00%-10.16%-10.99%+58.22%-73.78%TMCITreace Medical Concepts0.00%-5.83%+3.48%-12.34%-33.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems2.1396 of 5 stars3.52.00.00.00.62.50.6LUNGPulmonx3.1194 of 5 stars3.35.00.00.00.63.30.6OMOutset Medical1.6277 of 5 stars3.51.00.00.02.70.80.0TMCITreace Medical Concepts2.7459 of 5 stars3.22.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems 3.00Buy$24.00113.33% UpsideLUNGPulmonx 2.63Moderate Buy$11.53265.87% UpsideOMOutset Medical 3.00Buy$29.5069.35% UpsideTMCITreace Medical Concepts 2.33Hold$10.5286.14% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, DCTH, TMCI, and OM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025OMOutset MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$37.006/23/2025DCTHDelcath SystemsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.005/23/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $29.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.605/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$53.85M7.28N/AN/A$2.15 per share5.23LUNGPulmonx$87.47M1.45N/AN/A$2.17 per share1.45OMOutset Medical$115.27M2.68N/AN/A$7.49 per share2.33TMCITreace Medical Concepts$209.36M1.70N/AN/A$1.81 per share3.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$26.39M-$0.50N/AN/AN/A-26.38%-29.44%-20.75%8/4/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)OMOutset Medical-$127.98M-$29.15N/A∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.85N/AN/AN/A-25.14%-48.69%-24.59%8/5/2025 (Estimated)Latest LUNG, DCTH, TMCI, and OM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OMOutset Medical-$1.76N/AN/AN/A$29.40 millionN/A8/5/2025Q2 2025TMCITreace Medical Concepts-$0.28N/AN/AN/A$47.08 millionN/A8/4/2025Q2 2025DCTHDelcath Systems$0.02N/AN/AN/A$22.84 millionN/A7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 million$19.80 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A15.9514.61LUNGPulmonx0.384.974.29OMOutset Medical0.578.376.74TMCITreace Medical Concepts0.514.503.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%LUNGPulmonx91.04%OMOutset MedicalN/ATMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.40%LUNGPulmonx6.80%OMOutset Medical2.40%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems6034.83 million28.77 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableOMOutset Medical52017.72 million17.30 millionNot OptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableLUNG, DCTH, TMCI, and OM HeadlinesRecent News About These CompaniesKornitzer Capital Management Inc. KS Sells 161,525 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 16, 2025 | marketbeat.comTreace Medical Concepts, Inc. Common Stock (TMCI) - NasdaqJuly 9, 2025 | nasdaq.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Recommendation of "Hold" by AnalystsJuly 7, 2025 | marketbeat.comLisanti Capital Growth LLC Makes New $2.12 Million Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)June 29, 2025 | marketbeat.comTMCI Treace Medical Concepts, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the companyJune 21, 2025 | finance.yahoo.comAttention Long-Term Treace Medical Concepts, Inc. (™CI) Shareholders: Grabar Law Office is Investigating Claims on Your BehalfJune 13, 2025 | investing.comKuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law FirmJune 11, 2025 | prnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025June 10, 2025 | accessnewswire.comATreace Medical Concepts, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff MotionJune 10, 2025 | globenewswire.comSecurities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents ShareholdersJune 10, 2025 | accessnewswire.comATMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 10, 2025 | globenewswire.comLost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & KorsinskyJune 10, 2025 | accessnewswire.comAClass Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & KorsinskyJune 10, 2025 | globenewswire.comTMCI DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 10, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalJune 10, 2025 | businesswire.comDid You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi & Korsinsky Urges Investors to Act Before June 10, 2025June 10, 2025 | accessnewswire.comAFINAL REMINDER TMCI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Treace Medical Concepts, Inc. Investors to Participate in the Class Action LawsuitJune 10, 2025 | accessnewswire.comALevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCIJune 10, 2025 | prnewswire.comShareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & KorsinskyJune 9, 2025 | accessnewswire.comATMCI FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 9, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUNG, DCTH, TMCI, and OM Company DescriptionsDelcath Systems NASDAQ:DCTH$11.25 -0.07 (-0.62%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.50 +0.25 (+2.26%) As of 07/18/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Pulmonx NASDAQ:LUNG$3.15 +0.06 (+1.94%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.12 -0.03 (-0.95%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Outset Medical NASDAQ:OM$17.42 -0.18 (-1.02%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$17.74 +0.31 (+1.81%) As of 07/18/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Treace Medical Concepts NASDAQ:TMCI$5.65 -0.14 (-2.42%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.72 +0.07 (+1.31%) As of 07/18/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
